Bempedoic Acid

As one of the largest API supplier worldwide, we are your reliable partner for the supply of high quality commercial quantities of Apremilast

As one of the largest API supplier worldwide, we are your reliable partner for the supply of high quality commercial quantities of Apremilast

As one of the largest API supplier worldwide, we are your reliable partner for the supply of high quality commercial quantities of Apremilast

A phosphodiesterase 4 inhibitor API used for psoriasis and psoriatic arthritis.

An HMG-CoA reductase inhibitor API used to lower cholesterol and reduce cardiovascular risk.

A cytidine nucleoside analog API used as a DNA methyltransferase inhibitor in myelodysplastic syndromes.

An alkylating antineoplastic API used in hematologic cancers.

An anticholinergic API used for Parkinsonian symptoms and drug induced extrapyramidal reactions.

A reversible proteasome inhibitor API used in multiple myeloma and mantle cell lymphoma.

A multikinase inhibitor API used in renal cell carcinoma, hepatocellular carcinoma and thyroid cancer.

An oral fluoropyrimidine prodrug API used as an antineoplastic agent.

An epoxyketone proteasome inhibitor API used in multiple myeloma therapy.

Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic and Wegovy, addressing the growing demand for accessible treatments in India.

This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? 

Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. 

Aurigene Pharma announces the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.
As a first step of investment plan, Aurigene is investing $40m in an R&D and pilot scale facility at Genome Valley, a well-known Biotechnology Park in Hyderabad. This facility will meet the process development and clinical supply needs of global biotech companies. The facility is planned to be fully operational in first half of 2024.This complements Aurigene’ s strong foundation in biotherapeutics discovery, contributing to accelerating global R&D-driven (bio)pharma companies’ biologics journey to the market by offering end-to-end and high-quality services for antibodies, proteins, and viral vectors.

In this latest episode from the CPHI Podcast Series, Digital Editor Lucy Chard speaks to Sanjay Sharma, Global Head of Manufacturing, from Dr Reddy’s. Sanjay has over 26 years of experience in roles encompassing sales, the supply chain, and technical operations.